206 related articles for article (PubMed ID: 35152176)
1. Generation of a human induced pluripotent stem cell line PUMCHi019-A from a dominant optic atrophy patient with an OPA1 mutation.
Sun Z; Wu S; Zhu T; Wei X; Han X; Zou X; Sui R
Stem Cell Res; 2022 Apr; 60():102705. PubMed ID: 35152176
[TBL] [Abstract][Full Text] [Related]
2. Generation of induced pluripotent stem cells from a patient with hearing loss carrying OPA1 c.1468T>C (p.Cys490Arg) variant.
Chan YH; Ho CH; Tsai CY; Lu YC; Lin PH; Chen TC; Chen YT; Huang CY; Liu TC; Hsu CJ; Wu CC
Stem Cell Res; 2022 Oct; 64():102903. PubMed ID: 36075118
[TBL] [Abstract][Full Text] [Related]
3. Modelling autosomal dominant optic atrophy associated with OPA1 variants in iPSC-derived retinal ganglion cells.
Sladen PE; Jovanovic K; Guarascio R; Ottaviani D; Salsbury G; Novoselova T; Chapple JP; Yu-Wai-Man P; Cheetham ME
Hum Mol Genet; 2022 Oct; 31(20):3478-3493. PubMed ID: 35652445
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a human DOA 'plus' iPSC line, IISHDOi003-A, with the mutation in the OPA1 gene: c.1635C>A; p.Ser545Arg.
Zurita-Díaz F; Galera-Monge T; Moreno-Izquierdo A; Corton M; Ayuso C; Garesse R; Gallardo ME
Stem Cell Res; 2017 Oct; 24():81-84. PubMed ID: 29034899
[TBL] [Abstract][Full Text] [Related]
5. Derivation of a human DOA iPSC line, IISHDOi006-A, with a mutation in the ACO2 gene: c.1999G>A; p.Glu667Lys.
Cerrada V; García-López M; Moreno-Izquierdo A; Villaverde C; Zurita O; Martin-Merida MI; Arenas J; Ayuso C; Gallardo ME
Stem Cell Res; 2019 Oct; 40():101566. PubMed ID: 31509793
[TBL] [Abstract][Full Text] [Related]
6. Generation of a human iPSC line from a patient with an optic atrophy 'plus' phenotype due to a mutation in the OPA1 gene.
Galera-Monge T; Zurita-Díaz F; Moreno-Izquierdo A; Fraga MF; Fernández AF; Ayuso C; Garesse R; Gallardo ME
Stem Cell Res; 2016 May; 16(3):673-6. PubMed ID: 27346197
[TBL] [Abstract][Full Text] [Related]
7. Generation of an induced pluripotent stem cell line BIOi002-A from a patient with autosomal dominant optic atrophy.
Zhang XH; Xie Y; Xu K; Li Y
Stem Cell Res; 2021 May; 53():102278. PubMed ID: 33752025
[TBL] [Abstract][Full Text] [Related]
8. Modeling autosomal dominant optic atrophy using induced pluripotent stem cells and identifying potential therapeutic targets.
Chen J; Riazifar H; Guan MX; Huang T
Stem Cell Res Ther; 2016 Jan; 7():2. PubMed ID: 26738566
[TBL] [Abstract][Full Text] [Related]
9. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model.
Sarzi E; Seveno M; Piro-Mégy C; Elzière L; Quilès M; Péquignot M; Müller A; Hamel CP; Lenaers G; Delettre C
Sci Rep; 2018 Feb; 8(1):2468. PubMed ID: 29410463
[TBL] [Abstract][Full Text] [Related]
10. OPA1: How much do we know to approach therapy?
Del Dotto V; Fogazza M; Lenaers G; Rugolo M; Carelli V; Zanna C
Pharmacol Res; 2018 May; 131():199-210. PubMed ID: 29454676
[TBL] [Abstract][Full Text] [Related]
11. Genetic screening for OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies.
Yu-Wai-Man P; Shankar SP; Biousse V; Miller NR; Bean LJ; Coffee B; Hegde M; Newman NJ
Ophthalmology; 2011 Mar; 118(3):558-63. PubMed ID: 21036400
[TBL] [Abstract][Full Text] [Related]
12. Characterization of human induced pluripotent stem cells line (PNUSCRi004-A) from a Parkinson's disease patient carrying L483P, A495P and V499V mutations.
Moon HJ; Lee N; Moon JY; Lee JH; Kim JH
Stem Cell Res; 2023 Apr; 68():103051. PubMed ID: 36805467
[TBL] [Abstract][Full Text] [Related]
13. Defective mitochondrial adenosine triphosphate production in skeletal muscle from patients with dominant optic atrophy due to OPA1 mutations.
Lodi R; Tonon C; Valentino ML; Manners D; Testa C; Malucelli E; La Morgia C; Barboni P; Carbonelli M; Schimpf S; Wissinger B; Zeviani M; Baruzzi A; Liguori R; Barbiroli B; Carelli V
Arch Neurol; 2011 Jan; 68(1):67-73. PubMed ID: 20837821
[TBL] [Abstract][Full Text] [Related]
14. An integration-free iPSC line ZZUNEUi029-A derived from peripheral blood mononuclear cells of a patient with familial hypercholesterolemia carrying a mutation in LDLR gene.
Zhu K; Zhao J; Qin F; Chen X; Xu H; Li X; Tao H
Stem Cell Res; 2023 Sep; 71():103182. PubMed ID: 37586167
[TBL] [Abstract][Full Text] [Related]
15. OPA1 mutations associated with dominant optic atrophy influence optic nerve head size.
Barboni P; Carbonelli M; Savini G; Foscarini B; Parisi V; Valentino ML; Carta A; De Negri A; Sadun F; Zeviani M; Sadun AA; Schimpf S; Wissinger B; Carelli V
Ophthalmology; 2010 Aug; 117(8):1547-53. PubMed ID: 20417568
[TBL] [Abstract][Full Text] [Related]
16. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations.
Yu-Wai-Man P; Griffiths PG; Burke A; Sellar PW; Clarke MP; Gnanaraj L; Ah-Kine D; Hudson G; Czermin B; Taylor RW; Horvath R; Chinnery PF
Ophthalmology; 2010 Aug; 117(8):1538-46, 1546.e1. PubMed ID: 20417570
[TBL] [Abstract][Full Text] [Related]
17. Heterozygous deletion of the OPA1 gene in patients with dominant optic atrophy.
Hayashi T; Sasano H; Katagiri S; Tsunoda K; Kameya S; Nakazawa M; Iwata T; Tsuneoka H
Jpn J Ophthalmol; 2017 Sep; 61(5):395-401. PubMed ID: 28668999
[TBL] [Abstract][Full Text] [Related]
18. Generation of three human iPSC lines from a retinitis pigmentosa family with SLC7A14 mutation.
Li YP; Liu H; Jin ZB
Stem Cell Res; 2020 Dec; 49():102075. PubMed ID: 33207307
[TBL] [Abstract][Full Text] [Related]
19. Distributed abnormalities of brain white matter architecture in patients with dominant optic atrophy and OPA1 mutations.
Rocca MA; Bianchi-Marzoli S; Messina R; Cascavilla ML; Zeviani M; Lamperti C; Milesi J; Carta A; Cammarata G; Leocani L; Lamantea E; Bandello F; Comi G; Falini A; Filippi M
J Neurol; 2015 May; 262(5):1216-27. PubMed ID: 25794858
[TBL] [Abstract][Full Text] [Related]
20. Generation of a healthy heavy smoker patient-derived induced pluripotent stem cell line UHOMi007-A from peripheral blood mononuclear cells.
Ahmed E; Fieldès M; Bourguignon C; Mianné J; Petit A; Amel N; Foisset F; Bourdais C; Vachier I; Assou S; De Vos J; Bourdin A
Stem Cell Res; 2024 Jun; 77():103437. PubMed ID: 38723411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
